WaveMan
WaveMan · Company
CELU · Celularity Inc
> Search tickers & screens ⌘K
LIVE
← All companies

CELU Celularity (CELU) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001752828
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
19
13F, latest reported quarter

CELU filings, in plain words

Read the full summary

The latest 5% ownership filing is a 13D by PHILP & DANIELE BARACH FAMILY TRUST, filed 2026-04-03, for 9.6% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Celularity insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Celularity Inc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Genting Berhad
BUY
2024-01-17 SECtraded 2024-01-12
21,410,983
$5.4M
-74.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 41.6% of the 51,473,762 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Genting Berhad bought about $5.4M of CELU on Jan 12, 2024, the largest insider purchase at the company on our record; 19 funds added in the latest 13F quarter.
Hariri Robert J
Chief Executive Officer
BUY
2023-10-10 SECtraded 2023-10-05
3,050,427
$488.1K
-68.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Sep 29, 2023.
  • -59.5% median (-48.7% mean) 90-day return after 4 previous buys.
  • The trade is 10.7% of the 28,570,434 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hariri Robert J bought about $488.1K of CELU on Oct 5, 2023; 19 funds added in the latest 13F quarter.
Hariri Robert J
Chief Executive Officer
BUY
2023-10-10 SECtraded 2023-10-05
6,307,158
$1.0M
-68.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Sep 29, 2023.
  • -59.5% median (-48.7% mean) 90-day return after 4 previous buys.
  • The trade is 24.7% of the 25,520,007 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hariri Robert J bought about $1.0M of CELU on Oct 5, 2023; 19 funds added in the latest 13F quarter.
Sorrento Therapeutics, Inc.
SELL
2023-10-05 SEC
6,307,158
-
-65.6%
Hariri Robert J
Chief Executive Officer
BUY
2023-10-10 SECtraded 2023-09-29
9,064,539
$1.5M
-68.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Nov 30, 2022.
  • -59.9% median (-59.7% mean) 90-day return after 3 previous buys.
  • The trade is 47.2% of the 19,212,849 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hariri Robert J bought about $1.5M of CELU on Sep 29, 2023, the largest insider purchase at the company on our record; 19 funds added in the latest 13F quarter.
9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 4 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
19 funds bought in last quarter
below 70% of Pharma & Biotech
Revenue
-51.0% year over year
below 80% of Pharma & Biotech
Margin
-345.4% net margin
below 74% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.8% of the float short (float per yahoo 2026-10-26) · 2.5 days to cover · settled 2026-09-30
below 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CELU

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-62.3%12M
-70%-45%-20%+6%2025-102025-122026-022026-042026-062026-082026-10 2026-04-03 · PHILP & DANIELE BARACH FAMILY TRUST filed a 5%+ stake (9.56%)2026-04-03 · PHILIP A. BARACH filed a 5%+ stake (9.56%)2026-04-03 · DANIELE BARACH filed a 5%+ stake (9.56%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CELU: institutional holders (13F)

13F holdings, latest reported quarter
C V STARR & CO INC
764,069 sh
$1.6M
VANGUARD CAPITAL MANAGEMENT LLC
621,105 sh
$371.4K
GEODE CAPITAL MANAGEMENT, LLC
167,150 sh
$100.0K
CITADEL ADVISORS LLC
99,054 sh
$59.2K
VANGUARD FIDUCIARY TRUST CO
79,874 sh
$47.8K

Congress trades in CELU

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
PHILP & DANIELE BARACH FAMILY TRUST
Activist 13D · 2026-04-03
9.56%
PHILIP A. BARACH
Activist 13D · 2026-04-03
9.56%
DANIELE BARACH
Activist 13D · 2026-04-03
9.56%

CELU planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CELU mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$105.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$99.3K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$8.5K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$21.4K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$20.9K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$272.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
0 active
3
Phase 2
0 active
3
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 19 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CELU financials

Revenue growth
-51.0%
XBRL, annual
Net margin
-345.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$18.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-245.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$9.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.22x
TTM operating cash flow over long-term 2025-12-31 (6 months older than the period end) plus current 2025-06-30 (12 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-42.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-112.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$63.9M
market value at close 2026-10-26 on 2026-10-19 shares, plus long-term 2025-12-31 (6 months older than the period end) plus current 2025-06-30 (12 months older than the period end), minus cash 2026-06-30
FCF yield
-37.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$26.6M$54.2M$22.8M$18.0M
Gross profitn/an/a$6.8M-$1.7M
Operating income-$61.3M-$38.4M-$192.3M-$25.6M
Net income-$91.7M-$57.9M-$196.3M$14.2M
EPS (diluted)-3.59-2.64-11.020.95
Operating cash flow-$13.3M-$6.4M-$38.7M-$137.9M
Cash$6.2M$738.0K$227.0K$14.0M
Long-term debt$33.8Mn/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

CELU Stock Sonar score 5/7 axes

Find similar shapesCompare

CELU ranks highest on risk and compliance (80th percentile) and financial health (64th), and lowest on growth (20th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
36
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-42.4% · 50 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-112.8% · 23 pct, sector of 576
Financial health
64
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.22x · 64 pct, sector of 371
Growth
20
Inputs
  • Revenue growth, YoY-51.0% · 20 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
30
Inputs
  • Funds adding, latest quarter19 · 30 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
80
Inputs
  • Short interest, % of float+1.8% · 75 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+4.7% · 84 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies